HR Execs on the Move

Hyasynth Bio

www.hyasynthbio.com

 
Natural molecules or derivatives make up more than half of the current drugs on the market with applications to nearly every disease known to humans. Salicylic acid, morphine, cannabinoids and insulin are a few examples. Our specialty is in producing these, and new targets, using a fast and scalable platform based on engineered microbes.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details
Kevin Chen
Co Founder and Chief Executive Officer Profile

Similar Companies

Quintiles

Quintiles is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Enzyvant

Enzyvant is also advancing the development of RVT-802, an investigational tissue-based biologic therapy for the potential treatment of primary immune deficiency associated with complete DiGeorge Syndrome. RVT-802 has been granted orphan drug designation, Breakthrough Therapy designation, Regenerative Medicine Advanced Therapy designation, and pediatric rare disease designation by the U.S. Food and Drug Administration. Enzyvant anticipates a potential BLA filing for RVT-802 in the first half of 2018. Enzyvant plans to develop treatments for additional rare diseases with high unmet need.

Apollomics

At Apollomics, we are a purpose driven company imagining a world without cancer. We let science drive our decision making to advance our programs. We believe in the power of partnerships to enhance our pipeline and broaden the patient populations we serve.

Somaxon Pharmaceuticals, Inc.

Somaxon Pharmaceuticals, Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.

Delix Therapeutics

Delix Therapeutics is applying modern tools of pharmaceutical development to some of natures most ancient therapies, psychedelics.